Disclaimer

The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Day

September 28, 2021
Deelname aan Next Generation Medtech & Device Panel op 5 oktober 2021 Gent, België – 28 september 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, de “Vennootschap”), een vernieuwer in de behandeling van diuretica-resistente vochtoverbelasting in leveraandoeningen, maligne ascites en hartfalen, kondigt vandaag aan dat Ian Crosbie, Chief Executive Officer, zal deelnemen aan een paneldiscussie...
Read More

PERSBERICHTEN

INSCHRIJVEN OP ONZE PERSBERICHTEN